UroGen Pharma URGN Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Net margin | -139.8%+0.5pp | -140.4%-16.7pp | -123.6%+47.0pp | -170.6%+60.1pp | |
| Efficiency | |||||
| Asset turnover | 0.5×+0.1× | 0.4×-0.1× | 0.5×0.0× | 0.5×+0.1× | |
| Liquidity | |||||
| Current ratio | 4×-2.0× | 6×+0.6× | 5.4×0.0× | 5.4×+0.3× | |
| Valuation | |||||
| Market capitalization | $1.1B+144% | $449.42M-17.1% | $541.95M+165% | $204.81M-3.9% | |
| Price / sales | 10×+5.0× | 5×-1.6× | 6.6×+3.4× | 3.2×-1.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are UroGen Pharma's profit margins?
- UroGen Pharma (URGN) runs a 89.7% gross margin and a -329.7% operating margin, with a -94.8% net margin.
- Where do UroGen Pharma's ratios come from?
- Every ratio is computed from UroGen Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.